信邦製藥(002390.SZ):譽衡集團累計減持1.1497%股份
格隆匯11月28日丨信邦製藥(002390.SZ)公佈,公司控股股東西藏譽曦的一致行動人哈爾濱譽衡集團有限公司(以下簡稱“譽衡集團”)因涉及債務違約事宜,近期被動減持了公司部分股份。截至2019年11月27日,譽衡集團已累計減持公司股份1916.77萬股,佔公司總股本的比例達到1.1497%。
截至2019年11月27日,西藏譽曦及其一致行動人譽衡集團仍持有公司股份3.61億股,佔公司總股本的比例為21.6746%。本次股份被動減持不會導致公司控制權發生變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.